CA
CLPT icon

Clearstead Advisors’s ClearPoint Neuro CLPT Stock Holding History

Clearstead Advisors’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Buy
+1
New +$12 ﹤0.01% 3590

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CCM
Conway Capital Management Burbank, California $225M AUM 19.09% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Clearstead Advisors's CLPT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in ClearPoint Neuro (CLPT) in Q2 2026: 1 share worth $18. The stake represents ﹤0.01% of the portfolio and ranks #3590 among its holdings.

46 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Clearstead Advisors held 1 share of ClearPoint Neuro worth $18 as of Q2 2026.
  • ClearPoint Neuro was a new Clearstead Advisors position in Q2 2026.
  • ClearPoint Neuro made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3590 holding.
  • 46 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.